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Abstract 
BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is a serious neonatal problem which 
has a high mortality rate even with advanced modes of mechanical ventilation. Pentraxin 3 is one of the long 
pentraxins, which plays an essential role in regulation of cell proliferation and angiogenesis. 
AIM: This study aims to assess serum pentraxin 3 levels in neonates with pulmonary arterial hypertension and 
compare them in those who have other congenital heart diseases and healthy neonates. Also, we intended to 
evaluate serum levels of CRP as a mediator of inflammation in the studied groups. 
METHODS: The study is a case-control study. Cases were recruited from El Galaa Teaching Hospital, classified 
into three groups; each group had thirty cases. The first one: cases with pulmonary hypertension (PHT), the 
second one: cases with congenital heart diseases (CHD) without pulmonary hypertension and the third group 
included healthy neonates. All participants were subjected to full history taking and full clinical examination. 
Diagnosis of congenital heart disease and pulmonary hypertension was made according to echocardiographic 
ﬁndings by pediatric cardiologist using echocardiography machine. Laboratory investigations included 
measurement of serum pentraxin 3, Routine CBC, CRP. 
RESULTS: This study found that the mean serum pentraxin 3 in PHT neonates was significantly higher than that 
of the control and CHD neonates (p ≤ 0.001, p = 0.02 respectively). Also, the mean Pentraxin3 of the CHD 
neonates was significantly higher than that of the control (p = 0.06). Also, the mean CRP of the PHT neonates 
was significantly higher than that of the control (p = 0.01). Regression analysis showed that Pentraxin3 was the 
main predictor of PAP (P = 0.01). 
CONCLUSION: Serum pentraxin 3 is significantly elevated in neonates with pulmonary hypertension, so 
measurement of pentraxin 3 levels in neonates may be valuable as a predictor for pulmonary hypertension in 
neonates. 
 
 
 
 
 
 
Introduction 
 
Persistent pulmonary hypertension of the 
newborn (PPHN) is considered a serious condition 
that appears in the neonatal period, which is always 
complicated by high morbidity and mortality. It is due 
to that the neonate fails to make a postnatal change 
from a high resistance fetal pulmonary circulatory 
state to a low resistance pulmonary circulation [1]. 
This low pulmonary blood flow secondary to increased 
pulmonary vascular resistance counteract potent gas 
exchange in the lungs prompting severe respiratory 
distress and decreased blood oxygen level in the 
neonate [2]. Data suggested that PPHN happens in 1-
2 infants / 1000 live births [3]. A recent study was 
performed in Egypt found that PPHN was found in 5% 
of the studied population [4]. The neonate has PPH is 
usually term or late-preterm and usually is not 
associated with congenital anomalies. Affected 
neonate complains shortly after birth with severe 
shortness of breath that needs mechanical ventilation 
[5]. In spite of different management procedures such 
as nitric oxide, aggressive mechanical ventilation and 
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extracorporeal membrane oxygenation (ECMO), the 
mortality rate for this disease is about 10-20% of 
affected neonates [6]. This aggressive treatment and 
occurrence of hypoxemia expose these neonates to 
have long-term sequelae including chronic lung 
disease, seizures, and neurological developmental 
problems [7].  
Pentraxin 3 is a subclass of long pentraxins 
which is synthesised by fibroblasts, smooth muscle 
cells and endothelium. Also, innate immune cells 
during inflammation secrete pentraxin 3. It plays a 
vital role in cell proliferation regulation and 
angiogenesis [8]. Serum levels of CRP are mediators 
of inflammation [9]. CRP is considered one of the 
short pentraxin which is produced in the liver in case 
of systemic inflammation [10].  
Using echocardiography has further 
expanded as an adjunct to physical examination to 
improve diagnostic accuracy and risk of cardiac 
diseases [11]. 
Fractional shortening (FS) is used to asses 
left ventricular dysfunction. It simply measures the 
degree of shortening of the diameter of left ventricle 
between end-diastole and end-systole. It is one of the 
most important measures in functional 
echocardiography [12]. 
The aim of this study was to evaluate serum 
pentraxin 3 levels in neonates with pulmonary arterial 
hypertension and compare them with those who have 
other congenital heart diseases and healthy neonates. 
Also, we intended to evaluate serum levels of high 
sensitive-CRP (hs-CRP), as a mediator of 
inflammation in the three studied groups. 
 
 
Material and Methods 
 
This study is a case-control study. Studied 
cases were recruited from El Galaa Teaching 
Hospital. It was approved by the local ethical 
committee of the National Research Center, and 
parental written informed consent was obtained from 
all study participants. Participants were classified into 
three groups; each group had thirty cases. The first 
one: cases with pulmonary hypertension, the second 
one: cases with congenital heart diseases with normal 
pulmonary pressure and the third group included 
healthy neonates. They were age, sex and gestation 
matched with neonates of other three groups. All 
participants were subjected to full history taking and 
full clinical examination. Demographic and clinical 
data such as age, sex, birth weight, and gestational 
age were documented in all participants. 
Diagnosis of congenital heart disease, 
pulmonary hypertension and other cardiac 
measurements including fractional shortening (FS) 
were made according to echocardiographic ﬁndings 
performed by pediatric cardiologist using 
echocardiography machine (Sonosite®, USA, probe 
5–8 Hz) [13]. Neonates meeting any of the following 
criteria were excluded from the study: diagnosis of 
proven sepsis by positive blood culture, disseminated 
intravascular coagulation, severe hypoxic respiratory 
failure, low Apgar score, non-congenital heart 
diseases (e.g., endocarditis) or maternal history of 
chorioamnionitis. 
Venous blood sample (2 ccs) was taken from 
each participant and serum was separated and stored 
at -30 until collection of all the samples then 
laboratory investigations were done. Laboratory 
investigations included measurement of serum 
pentraxin 3, Routine CBC. Serum Pentraxin 3 (PTX3) 
level was assessed by enzyme-linked immunosorbent 
assay (ELISA) following instructions of the kits 
purchased from Sino Gene Clon Biotech Co., Ltd. 
Catalog No: SG-10465. Serum hs-CRP levels were 
determined with an enzyme-linked immunosorbent 
assay (ELIZA) technique using commercial kits 
(BioCheck, Inc 323 Vintage Park Drive Foster City, 
CA 94404) and the sensitivity of detection level was 
0.01 mg/dl. 
 
Statistical analysis 
Data entry was carried out on excel sheet and 
analysis was done using SPSS software program 
version 22 (SSPS Inc., Pennsylvania, USA). Mean± 
SD was used to present quantitative data. T-test was 
done for comparison between two means. Pearson’s 
correlation analysis was performed to estimate the 
association between variables. Linear regression 
analysis was performed to identify the main predictors 
of PAP. P-value was considered statistically 
significant when P was < 0.05. 
 
 
Results 
 
Subjects in this study were classified into 
three groups; each group had thirty subjects. 
Table 1 shows the demographic and 
laboratory data of the studied groups. Comparison 
between PHT, CHD without pulmonary hypertension 
and control groups as regards different variables were 
shown in Table 1. No significant difference was found 
between the studied groups as regards age, GA and 
FS. As regards laboratory investigations, it was found 
that the mean CRP of the PHT group was significantly 
higher than that of the control (p = 0.01). Also, serum 
pentraxin 3 in PHT group was significantly higher 
compared to the control and CHD groups (p ≤ 0.001, 
p = 0.02 respectively). The mean Pentraxin3 of the 
CHD group was significantly higher in comparison to 
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controls (p = 0.06). 
Table 1: Demographic and Echocardiographic data in the 
studied groups 
Variable 
PHT 
(Mean ± SD) 
CHD 
(Mean ± SD) 
Control 
(Mean ± SD) 
P1 P2 P3 
Age (days) 3.95 ± 1.59 3.97 ± 2.36 4.37 ± 0.93 0.19 0.97 0.39 
Weight (Kg) 2.64 ± .0.71 2.97 ± 0.44 2.85 ± 0.53 0.171 0.03* 0.34 
GA (weeks) 37.03 ± 1.42 37.30 ± 1.37 37.53 ± 1.72 0112 0.42 0.46 
PAP  
(mm Hg) 
62.15 ± 14.48 28.7 ± 7.3   ≤ 0.001  
FS (%) 40.38 ± 3.18 41.10 ± 2.06   0.28  
CRP (mg/dl) 2.88 ± 0.91 2.53 ± 0.90 2.40 ± 0.50 0.01* 0.12 0.48 
Pentraxin 3 (µg/l) 7.60 ± 2.17 6.38 ± 2.20 5.53 ± 0.84 ≤ 0.001* 0.02* 0.06* 
P1: PHT Vs Control P2: PHT Vs CHD P3: CHD Vs Control; PHT: neonates with pulmonary 
hypertension PAP: Pulmonary artery pressure; CHD: Neonates with congenital heart 
disease without pulmonary hypertension; GA: Gestational age FS: Fractional shortening; 
*P < 0.05, the relationship is significant. 
 
Multiple correlations were calculated between 
serum pentraxin 3 and all other variables. They 
showed that PAP was positively correlated with serum 
pentraxin 3 (as shown in Figure 1) and FS (p = 0.009, 
p = 0.011 respectively). 
 
Figure 1: Correlation between PAP and serum pentraxin 3 
 
To show the influence of pentraxin 3 and CRP 
on PAP as a dependent factor, we did linear 
regression analysis. This analysis showed that 
Pentraxin3 was the main predictor of PAP (P = 0.01), 
as shown in Table 2. 
Table 2: Predictive factors for increased PAP in the PHT group 
as estimated by linear regression 
Model  
Unstandardized 
Coefficients 
Standardised 
Coefficients t Sig. 
B Std. Error Beta 
1 
(Constant) 39.727 11.163  3.559 .001 
Pentraxin3 2.742 1.011 .410 2.712 .010 
CRP .550 2.405 .035 .229 .820 
*P < 0.05, the relationship is significant. 
 
 
 
Discussion 
 
Pulmonary hypertension is one of the serious 
conditions in neonates which may be idiopathic, 
associated with congenital heart disease or lung 
disease and postoperative. In this study, it was found 
that the mean serum pentraxin 3 in neonates with 
PHT was significantly higher than that of the control 
and neonates with other CHD with no PHT. Also, the 
mean Pentraxin 3 of the later group was significantly 
higher than that of the control. This was in agreement 
with several studies which found that the mean serum 
pentraxin 3 in neonates with PHT was significantly 
higher than that of the control and neonates with other 
CHD [14], [15], [16]. Also, we found that the mean hs-
CRP of the PHT neonates was significantly higher 
than that of the control. 
Similarly, other studies found that hs-CRP 
was significantly elevated in PHT patients. They 
added that inflammation is a contributing factor to the 
progression of pulmonary hypertension [15], [16], hs-
CRP is one of the short pentraxins and is strongly 
released secondary to inflammation. To clarify our 
results, multiple correlations were calculated between 
serum pentraxin3 and all other variables. It showed 
that PAP was positively correlated with serum 
pentraxin 3. This may be explained by that pentraxin 3 
has a role in angiogenesis and vascular diseases. It is 
secreted at sites of inflammation not only by 
endothelial cells but also by macrophages and 
monocytes infiltrating sites of inflammation that 
happens in pulmonary hypertension [17]. No 
correlation was found between serum pentraxin 3 and 
hs-CRP as found in previous study [15]. To show the 
influence of pentraxin 3 and CRP on PAP as a 
dependent factor, we did linear regression analysis. 
This analysis showed that Pentraxin3 was the main 
sensitive biomarker of PAP than hs-CRP. This is 
similar to findings of Tamura et al., who added that hs-
CRP is increased to a significant degree in the PAH 
group. This study also found that PAP was positively 
correlated with FS [15]. 
In conclusion, serum pentraxin 3 is an 
important sensitive biomarker of pulmonary artery 
pressure. It is elevated in pulmonary artery 
hypertension, so measuring serum pentraxin3 might 
be useful in prediction and progression of pulmonary 
artery hypertension in neonates.  
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